Ascendis Pharma A/S Says Preliminary 58-Week Results From Open-Label Extension Of Phase 2 PaTH Forward Trial Of TransCon PTH In Adult Hypoparathyroidism Demonstrated Durable Benefit And Well-Tolerated Safety Profile

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!